All In Biotech

Drug Trial Radar · NCT05945732

DESTINY Breast Respond HER2-(Ultra)Low Europe

A Prospective, Non-interventional Study (NIS) With Trastuzumab Deruxtecan For Patients With HER2-(Ultra)Low Expressing Unresectable and/or Metastatic Breast Cancer Accompanied By a Disease Registry of Patients Treated With Conventional Chemotherapy (DESTINY Breast Respond HER2-(Ultra)Low Europe)

Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

2,295

Planned (sponsor's estimate)

Start

Oct 24, 2023

Primary completion

Dec 31, 2030

Study completion Dec 31, 2030

Sponsor

Sponsor type
Industry
First posted
Jul 14, 2023

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Trastuzumab deruxtecan (T-DXd) as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. Based on the extended therapeutic indication of Trastuzumab deruxtecan (Enhertu®), a new patient population will be enrolled, comprising adult patients with unresectable or metastatic HR-positive, HER2-low, or HER2-(ultra)low breast cancer who have received at least one endocrine therapy in the metastatic setting and are not considered suitable for endocrine therapy as the next line of treatment.

Conditions

  • Unresectable Breast Cancer
  • Metastatic Breast Cancer
  • HER2-low Expressing Breast Cancer
  • HER2-(Ultra)Low Expressing Breast Cancer

Interventions

  • Trastuzumab deruxtecanDrug

    This is a non-interventional study and medication will be administered according to the SmPC as local standard of care and as part of the routine clinical practice. Trastuzumab (T-DXd) to be administered according to the SmPC. Conventional therapy (eg. capecitabine, eribulin, gemcitabine, paclitaxel, nab paclitaxel) to be administered according to the SmPC.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Real World Time to Next Treatment (rwTTNT1) in Participants With Unresectable and/or Metastatic Breast CancerTime frame: Baseline up to approximately 37 months

Locations

216 sites in 10 countries. Site status is shown where the registry gives one.

  • Medizinische Universität Graz

    Graz, Austria · Terminated

  • Medizinische Universität Graz

    Graz, Austria · Recruiting

  • Medizinische Universität Innsbruck

    Innsbruck, Austria · Recruiting

  • Klinikum Klagenfurt am Wörthersee

    Klagenfurt, Austria · Recruiting

  • LKH Hochsteiermark-Leoben

    Leoben, Austria · Withdrawn

  • Ordensklinikum Linz GmbH Barmherzige Schwestern

    Linz, Austria · Recruiting

  • Interne II, LKH Feldkirch

    Rankweil, Austria · Active not recruiting

  • KH der Barmherzigen Brüder Salzburg

    Salzburg, Austria · Recruiting

  • Uniklinikum Salzburg

    Salzburg, Austria · Recruiting

  • Medical University of Vienna

    Vienna, Austria · Recruiting

  • Medizinische Universität Wien

    Vienna, Austria · Terminated

  • Krankenhaus Hietzing

    Vienna, Austria · Recruiting

  • Salzkammergut Klinikum Vöcklabruck

    Vöcklabruck, Austria · Recruiting

  • Klinikum Wels-Grieskirchen GmbH

    Wels, Austria · Active not recruiting

  • Landesklinikum Wiener Neustadt

    Wiener Neustadt, Austria · Recruiting

  • ASZ Aalst

    Aalst, Belgium · Active not recruiting

  • Chirec Delta Hospital

    Auderghem, Belgium · Active not recruiting

  • Imeldaziekenhuis Bonheiden

    Bonheiden, Belgium · Active not recruiting

  • AZ Klina

    Brasschaat, Belgium · Active not recruiting

  • AZ Sint-Jan Brugge av

    Bruges, Belgium · Active not recruiting

  • CHU Brugmann

    Brussels, Belgium · Active not recruiting

  • Cliniques universitaires Saint-Luc

    Brussels, Belgium · Active not recruiting

  • Chu Helora- Hôpital de La Louvière- site Jolimont

    Haine-Saint-Paul, Belgium · Active not recruiting

  • Jessa Ziekenhuis

    Hasselt, Belgium · Active not recruiting

  • CHU Tivoli

    La Louvière, Belgium · Active not recruiting

  • CHC MontLegia

    Liège, Belgium · Active not recruiting

  • Hôpital de la Citadelle

    Liège, Belgium · Active not recruiting

  • CHU UCL Namur/Site Sainte Elisabeth

    Namur, Belgium · Active not recruiting

  • Clinique Saint Pierre Ottignies

    Ottignies, Belgium · Active not recruiting

  • VITAZ

    Sint-Niklaas, Belgium · Active not recruiting

  • CHR Verviers East Belgium

    Verviers, Belgium · Active not recruiting

  • Aalborg Universitetshospital, Syd

    Aalborg, Denmark · Terminated

  • Aarhus University Hospital

    Aarhus N, Denmark · Active not recruiting

  • Herlev Hospital

    Herlev, Denmark · Active not recruiting

  • Onkologisk og Palliativ afdeling, Nordsjællands Hospital

    Hillerød, Denmark · Active not recruiting

  • Naestved Hospital

    Næstved, Denmark · Active not recruiting

  • Sygehus Sønderjylland, Sønderborg

    Sønderborg, Denmark · Terminated

  • CHU Amiens Picardie

    Amiens, France · Active not recruiting

  • Clinique de l'Europe

    Amiens, France · Active not recruiting

  • Hôpital Privé d'Antony

    Antony, France · Withdrawn

Showing 40 of 216 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.